Navigation Links
Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer

BUFFALO, N.Y., Feb. 25 /PRNewswire/ --  Kinex Pharmaceuticals opened a Phase 2 clinical trial to evaluate the safety and efficacy of KX2-391 in patients with bone-metastatic, castrate-resistant prostate cancer (CRPC) who have not had prior chemotherapy.  

The study will take place at the University of Chicago, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, the University of Wisconsin (Madison), the University of Washington (Seattle) and at Wayne State University. The lead Principal Investigator for the study is Dr. Michael Carducci from Johns Hopkins University.  

The Phase 2 single-arm study will enroll approximately 50 patients with progressive prostate cancer who will receive orally administered KX2-391 twice-daily for 24 weeks.  The primary endpoint of the study is to determine the number of patients who do not have clinical or radiographic progression after 24 weeks of treatment.  Approximately 70% of patients with progressive bone-metastatic prostate cancer who do not undergo treatment, will progress within 24 weeks.  The ability of KX2-391 to improve the outcome of CRPC patients who do not elect to be treated by chemotherapy will be determined.

KX2-391 is an inhibitor of Src kinase signaling and microtubule polymerization and has a broad range of activity in cancer cell lines, including those that are resistant to commonly used chemotherapeutic agents.  Preclinical studies have highlighted the ability of KX2-391 to inhibit the proliferation and metastasis of prostate cancer cell lines in mouse xenografts.

"Based on its mechanism of action and on Phase 1 clinical data, we expect KX2-391 to benefit men with CRPC.  This drug is well tolerated and provides an option for patients who do not want to proceed to chemotherapy," said Dr. Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals.

About Kinex Pharmaceuticals

Kinex is a Buffalo, NY based, privately held biopharmaceutical company committed to the discovery and development of novel therapeutics. The Company's platform technologies, Mimetica™ and Opal™, provide unique insight into the design and synthesis of target-based small molecule inhibitors that selectively act on proteins that play key roles in cancer and immuno-inflammatory diseases.

KX2-391 is currently being studied in a Phase 2 clinical trial in prostate cancer patients; additional Phase 2 oncology studies will commence later in 2010. KX2-361 is being developed for brain cancer; an IND is expected during the 4th quarter of 2010. In addition, Kinex is developing several other new product candidates that inhibit key immuno-inflammatory pathways.

For more information, visit

SOURCE Kinex Pharmaceuticals

Back to top



SOURCE Kinex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
2. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
3. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
4. Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
5. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
6. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
7. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
8. Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
9. Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
10. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
11. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
Post Your Comments:
(Date:11/24/2015)... 2015 Sectra (STO: SECT B) ... into a multi-year agreement to deploy Breast Imaging ... provide the Breast Center a future-proof platform capable of ... SECT B) announces that Breast Center of Acadiana ... Breast Imaging PACS in its two freestanding imaging centers. This ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
(Date:11/24/2015)... 2015 iRhythm Technologies, Inc. , a leading digital ... that it will participate in the 27th Annual Piper Jaffray Healthcare ... York, NY . Kevin King , Chief Executive ... 2015 at 8:50am ET. --> ... --> . --> iRhythm is a ...
Breaking Medicine Technology:
(Date:11/24/2015)... Peoria, IL (PRWEB) , ... November 24, 2015 , ... Dr. Rodney E. Willey ... His new venture, Koala Center for Sleep Disorders, provides treatment for snoring and ... dentists who have opened a Koala Center for Sleep Disorders in the US, one of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Bibliomotion is thrilled to ... Me about Reinvention and Diversity by Nancy M. Schlichting, Chief Executive Officer ... failing to adequately address the needs of patients and their families, shaped my desire ...
(Date:11/24/2015)... ... November 24, 2015 , ... World Patent ... Blending, a household invention that revolutionizes the vending machine industry by providing healthy ... is worth $2 billion," says Scott Cooper, CEO and Creative Director of World ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... announces Fragrance by Marcelle, a cosmetic invention which offers a combination of natural ... Market in the US is worth $3 billion annually," says Scott Cooper, CEO ...
(Date:11/24/2015)... ... , ... “I am so thrilled, as a newbie here, to leave a mark for the ... School Lounge Makeover® from California Casualty . Stephanie is in her fifth year teaching ... longer tenure. , “This is such an amazing school and we deserve a space where ...
Breaking Medicine News(10 mins):